Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia
Cancer · 2025
DOI: 10.1002/cncr.35641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Congxiao Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hos…. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Chinese Academy of Medical Science Innovation Fund for Medical Sciences, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
In acute myeloid leukemia (AML), further investigation is warranted to integrate measurable residual disease (MRD) with genetic characteristics for formulating a dynamic prognostic system for predicting response and selecting appropriate postremission therapeutic strategies.
Methods
The authors incorporated MRD with genetic risk classification and assessed its impact on transplantation decision making within different risk cohorts, comprising 769 patients with newly diagnosed AML across three clinical trials. Only patients who achieved complete remission (CR) within two courses of chemotherapy were selected.
Results
In the favorable‐risk and intermediate‐risk groups, patients who underwent transplantation according to the protocol experienced significant 3‐year overall survival (OS) benefits compared with those who did not (favorable‐risk group: hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20–0.73l p = .004; intermediate‐risk group: HR, 0.53; 95% CI, 0.33–0.85; p = .008). In the intermediate‐risk group, early detection of MRD positivity, even after the initial course of chemotherapy, was associated with a significantly elevated cumulative incidence of relapse (47.2% vs. 36.0%; p = .009) and a notable extension of OS with allogeneic hematopoietic stem cell transplantation (HR, 0.47; 95% CI, 0.28–0.79; p = .004). Conversely, patients who achieved MRD negativity at either of the two time points had comparable OS in the favorable‐risk and intermediate‐risk groups, regardless of whether they underwent transplant or not. In the adverse‐risk group, allogeneic hematopoietic stem cell transplantation led to improvements in OS irrespective of MRD status (HR, 0.51; 95% CI, 0.38–0.69; p < .001).
Conclusions
Early clearance of MRD demonstrated significant prognostic value, particularly for patients in the favorable‐risk and intermediate‐risk groups. Positive MRD status after two courses of intensive chemotherapy were associated with a higher relapse rate and inferior OS, necessitating allogeneic hematopoietic stem cell transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical Col…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Kaiqi Liu, Shaowei Qiu, Jianxiang Wang
Förderung
- Chinese Academy of Medical Science Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Tianjin Municipal Science and Technology Commission
Zitieren
APA
Zhang, C., Gu, R., Wang, H., Zhou, C., Li, Y., Liu, Y., Wei, S., Lin, D., Liu, K., Fang, Q., Gong, X., Gong, B., Qiu, S., Zhang, G., Liu, B., Wang, Y., Mi, Y., Wei, H., & Wang, J. (2025). Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.35641
Vancouver
Zhang C, Gu R, Wang H, Zhou C, Li Y, Liu Y, et al. Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.35641
BibTeX
@article{Zhang2025,
author = {Zhang, Congxiao and Gu, Runxia and Wang, Huijun and Zhou, Chunlin and Li, Yan and Liu, Yuntao and Wei, Shuning and Lin, Dong and Liu, Kaiqi and Fang, Qiuyun and Gong, Xiaoyuan and Gong, Benfa and Qiu, Shaowei and Zhang, Guangji and Liu, Bingcheng and Wang, Ying and Mi, Yingchang and Wei, Hui and Wang, Jianxiang},
title = {Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35641}
}
EUVIMED